Product Information
ACITRETIN 17.5 MG CAPSULE is a generic product labeled by Sigmapharm Laboratories LLC, priced at $4.5184 per EA under NDC 42794008108. Its NADAC has been published 127 times since Sep 2, 2015.
FDA first approved this application on May 22, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
17.5 mg/1
Manufacturer
Sigmapharm Laboratories LLCNDC
42794008108
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACITRETINApproval Type
Generic (ANDA)
FDA Application
ANDA204633FDA Approved
5/22/2015
TE Code
AB
On Market Since
9/16/2015
Pharmacological Classes
Price Statistics
The NADAC for ACITRETIN 17.5 MG CAPSULE has been published 127 times since Sep 2, 2015, and over the history we have for it it has declined 81.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.5184 per EA |
|---|---|
| All-time high | $24.1687 (Mar 16, 2016) |
| All-time low | $4.5184 (Sep 23, 2026) |
| 52-week high | $7.9486 |
| 52-week low | $4.5184 |
| Median price | $7.2216 |
| Average price | $11.2843 |
| Largest weekly change | +55.6% (Jan 21, 2026) |
| Weeks tracked | 127 |
| Tracking since | Sep 2, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ACITRETIN market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sigmapharm Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ACITRETIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACITRETIN 17.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ACITRETIN 17.5 MG CAPSULE, manufactured by Sigmapharm Laboratories LLC, is $4.5184 per EA (NDC 42794008108), effective Sep 30, 2026.
How has the price of ACITRETIN 17.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ACITRETIN 17.5 MG CAPSULE has declined 81.3%. It has been tracked across 127 weekly CMS publications since Sep 2, 2015.
What are the highest and lowest recorded NADAC prices for ACITRETIN 17.5 MG CAPSULE?
Since Sep 2, 2015, the NADAC for ACITRETIN 17.5 MG CAPSULE has ranged from a low of $4.5184 (Sep 23, 2026) to a high of $24.1687 (Mar 16, 2016), with a median of $7.2216 per EA.
Are there cheaper alternatives to ACITRETIN 17.5 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of ACITRETIN 17.5 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ACITRETIN 17.5 MG CAPSULE?
ACITRETIN 17.5 MG CAPSULE (NDC 42794008108) is labeled by Sigmapharm Laboratories LLC, and CMS classifies it as a generic product.